Share this article
Share this article
ResearchAndMarkets.com s offering.
By the middle of the decade, point of care testing is expected to reach 45 billion dollars annually. This should not be surprising. Globally, millions of dollars are spent annually on POC diagnostic testing, both professional testing and self-testing. In 2020, sales of POC testing reached $29,316 million. COVID-19 was a significant game changer in 2020. The number of new tests for POC COVID-19 was stunning.
In some segments, COVID-19 caused a contraction of the segment due to lockdown, closures, limited physician visits and a reduction in elective and outpatient surgery. The market is expected to resume pre-pandemic growth in all segments of the POC market. Certain segments will continue to advance significantly from 2021-2025.
Posted January 8th, 2021 for Myriad SALT LAKE CITY, Jan. 08, 2021 ( ) Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice
® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula
® (niraparib). myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. “Myriad’s myChoice test is the only one of its kind to be approved for reimbursement in Japan,” said Nicole Lambert, president of Myriad Genetic Laboratories. “This decision further advances precision medicine and helps ensure that more Japanese women have access to the most advanced therapies in their fight against ovarian cancer.”
Risk Disclaimer - By using this web site you agree to its terms and conditions.
All materials, including but not limited to articles, directories, photos, lists, etc., on this website are the sole property of ForexTV or the respective copyright holders and are intended for informational/educational purposes using hypothetical and sometimes anecdotal illustrations. The unauthorized use of any and all materials is prohibited and restricted by copyright law. Any use of materials on this site must be approved in advance by ForexTV.
Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and therefore you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading, and seek advice from an independent financial advisor if you have any
Point of Care Lipid Test Market: Global Analysis, Industry Growth, Current Trends and Forecast 2025 newyorktelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newyorktelegraph.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report provides reliable estimates and real-world forecasts for the In Vitro diagnostics industry for two decades.
In its latest report the analyst estimates the market for In Vitro diagnostic products, including instruments, reagents and associated supplies to be $83.3 billion dollars. This is a substantial increase over our 2019 estimates, with 9 billion dollars of revenue originating from molecular and antibody COVID-19 testing responsible for most of the growth. Other infectious diseases (particularly respiratory pathogens), advanced cancer IVDs and increasing used of critical care and hematology tests are among the factors for additional growth.